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Objective: To assess the cost-utility of the human papillomavirus (HPV) vaccination on the
prevention of cervical cancer in the Brazilian Amazon region.
Methods: A Markov cohort model was developed to simulate the natural evolution of HPV and
its  progress to cervical cancer, considering the current preventive programs and treatment
costs. The one-year transition probabilities were mainly based on empirical data of local
and national studies. The model evaluated the addition of the vaccine to three cervical
cancer-screening scenarios (0, 3 or 10 exams throughout life).
Results: The scenario of three Pap tests resulted in satisfactory calibration (base case).
The addition of HPV vaccination would reduce by 35% the incidence of cervical cancer
(70%  vaccination coverage). The incremental cost-effectiveness ratio was US$ 825 for each
quality-adjusted life year gained. The sensitivity analysis conﬁrms the robustness of this
result, and duration of immunity was the parameter with greater variation in incremental
cost-effectiveness ratio.
Conclusion: Vaccination has a favorable proﬁle in terms of cost-utility, and its inclusion in the
immunization schedule would result in a substantial reduction in incidence and mortality
of  invasive cervical cancer in the Brazilian Amazon region.
Custo-efetividade  da  vacina  contra  o  papilomavírus  humano  na  região
Amazônica  brasileira
r  e  s  u  m  o
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Câncer de colo de útero
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Objetivo: Avaliar a custo-efetividade da vacinac¸ão contra o papilomavírus humano (HPV) na
prevenc¸ão  do câncer de colo de útero na região Amazônica brasileira.
Métodos: Um modelo de coorte Markov foi desenvolvido para simular a história natural do
HPV  e seu progresso para câncer de colo de útero, considerando os atuais programas de
 Study conducted at the Universidade Federal de Rio Grande do Sul, Porto Alegre, RS, Brazil, and at the Fundac¸ão de Medicina Tropical,
Manaus, AM, Brazil.
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Vacina
Brasil
Região amazônica
prevenc¸ão e os custos de tratamento. As probabilidades de um ano de transic¸ão foram
baseadas principalmente em dados empíricos de estudos locais e nacionais. O modelo
avaliou a adic¸ão da vacina a três cenários de rastreio de câncer de colo de útero (0, 3 ou
10  exames ao longo da vida).
Resultados: O cenário de três exames de Papanicolau resultou em calibrac¸ão satisfatória
(caso base). A adic¸ão de vacinac¸ão contra o HPV reduziria em 35% a incidência de câncer de
colo de útero (70% de cobertura de vacinac¸ão). A razão incremental de custo-efetividade foi
US$  825 para cada ano de vida ajustado para qualidade ganho. A análise de sensibilidade
conﬁrma a robustez deste resultado, e a durac¸ão de imunidade foi o parâmetro com maior
variac¸ão  na razão incremental de custo-efetividade.
Conclusão: A vacinac¸ão tem um perﬁl favorável em termos de custo-utilidade, e sua inclusão
no  calendário de imunizac¸ão resultaria em reduc¸ão substancial de incidência e de mortali-
dade relacionadas ao câncer de colo de útero na região Amazônica brasileira.
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he implementation of screening programs for precursor
esions has reduced mortality due to cervical cancer (CC) in
eveloped countries in recent decades; however, infrastruc-
ure weaknesses and ﬁnancing difﬁculties for this strategy
ave limited CC control in developing countries.1,2
In Brazil, CC represents an important public health prob-
em. It is estimated that 22,000 new cases of CC will be
iagnosed in 2013,3 corresponding to an incidence rate of
7.5 cases per 100,000 women and to a mortality rate of 10.2
eaths per 100,000 women.2 In the Brazilian Amazon region,
he problem is even more  serious. Due to a low screening
overage for CC in the target population (less than 25%), a
igh incidence of the disease has been registered in that
rea (up to 46 cases/100,000 women), similar to the inci-
ence rates in low-income countries, such as Uganda and
ali.4
The ﬁnding that 70% of CC cases are caused by two
iral serotypes motivated the establishment of preventive
trategies based on vaccination against HPV.5 Currently, two
accines are available against HPV serotypes 16 and 18.6–8 Vac-
ines are recommended for girls before they engage in sexual
ntercourse, and they appear to have a satisfactory effective-
ess. The quadrivalent vaccine induces antibodies of high
fﬁcacy against HPV and sustains stable levels for at least ﬁve
ears, in addition to inducing robust immune memory,  sug-
esting that immunity is enduring.9 Vaccine cross-immunity
as also been documented, with a 40% reduced incidence of
re-malignant cervical lesions induced by other oncogenic
PV serotypes (serotypes 31 and 45).10
Many  questions have been raised about the role of vac-
ination in CC preventive strategies, such as its clinical
ffectiveness, target population, and duration of immunity,
ut the main concern addresses the economic implication
f the vaccine. Unfortunately, the real effects of HPV vacci-
ation on the incidence and mortality rates of CC won’t be
vailable for decades. In the absence of longitudinal clinical
tudies that evaluate all of these variables, economic mod-
© 20ls of analytical health decisions can be useful tools for the
valuation of preventive strategies, by transporting data from
mpirical studies into real-world simulations, allowing for
he management of uncertainties and variations. Therefore,cost-effectiveness analyses play a key role in the evaluation
and selection of strategies that should be implemented.
Until the present time, there have been limited data on the
clinical and economic impacts of HPV vaccination in Brazil,
particularly in the Amazon region, where screening programs
have historically not been able to overcome geographical iso-
lation and signiﬁcant cultural barriers, as in the case of native
indigenous populations. The present study aimed to conduct
a cost-effectiveness and cost-utility analysis of HPV vaccina-
tion in the Brazilian Amazon region, an area with high CC
incidence.
Methods
Analytical  decision  model
A Markov cohort model was developed as a dynamic, closed,
and deterministic decision analysis tool for the evaluation of
cost-effectiveness and cost-utility in preventive vaccination
(Fig. 1), using the TreeAge software (2009 version) (TreeAge
Software Inc. - Williamstown, MA,  USA).
The analysis was performed from the provider’s perspec-
tive (Brazilian Uniﬁed Health System). The target population
was preteen girls (12 years of age), independent of previous
sexual contact or HPV infection. The cohort time horizon
was lifetime. The model simulated the natural course of HPV
infection until its progression to invasive cervical cancer, tak-
ing into account the current prevention programs (Pap test)
in Brazil. For each strategy (screening plus vaccination or
screening only), the model incorporated health state transi-
tion probabilities, and the target population was followed-up
from adolescence until death in a hypothetical cohort.
The model incorporated the transition probabilities of
mutually exclusive health states that refer to one-year cycles.
The model simulated the transition probabilities for 70 years
from the age of vaccination (12 years of age). At each
transition, the model attributed the costs, quality of life,
and death expectation according to the individual’s health
condition. The transition probabilities were based on empiri-
lsevier Editora Ltda. Este é um artigo Open Access sob a licença de CC BY-NC-NDcal data from the medical literature and referred to transitions
from a healthy state to a possible HPV infection and low-
grade squamous intraepithelial lesion (LSIL) induction, which
could regress over time to normality, persist, or progress to
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Fig. 1 – Structure of the Markov decision model. The circle
above represents the decision of whether or not to
vaccinate. The squares represent the states of health, and
the arrows represent the transition probabilities. Each
individual is followed-up from 12 years of age until death.
At each one-year cycle, the individuals are at risk
of developing precursor lesions, cancer, or death.
59 years of age and decreases after 60 years of age.high-grade squamous intraepithelial lesion (HSIL). This, in
turn, could persist, regress to normality, or progress to local-
ized, regional, or metastatic invasive cancer (Fig. 1). Given the
development of cancer, each individual could continue to suf-
fer from the disease, evolve to death, or evolve to a disease-free
state. Each year, individuals would be under an age-speciﬁc
risk of death that is unrelated to cancer. The odds of death
unrelated to cancer are based on the life expectancy and mor-
tality curves of Northern Brazil.11 The probability of death
unrelated to cancer was calculated through the following for-
mula:
Probability of death (age) = 1 − [survival probability (age + 1)/
survival probability (age)]
Due to the low coverage of typical preventive vaginal cyto-
logical screening strategies of the Amazonian population, the
model was evaluated in three independent scenarios of vacci-
nation or non-vaccination.4 The scenario with no cytological
screening throughout life (natural history of HPV infection)
was compared with the scenarios for three and ten Pap
smear exams throughout a woman’s life. At each screening
event, cervical lesions would be found according to the crite-
ria (Pap test sensitivity and speciﬁcity) described by national
studies. The detection of cervical lesions would require follow-
up evaluations or treatment (colposcopy, cryosurgery, and/or
surgery), for which they have been assigned a likelihood of
success, costs, and implications for the quality of life
of the individuals of the cohort model. The economic analysis
adopted a 5% annual discount rate for the cost and out-
come, with the intent to convert future values into present
values.12 0 1 3;5  9(5):442–451
Model  parameters  and  presumption  of  base  case
The cohort’s transition probabilities from a state of health to
another were established based on data from published stud-
ies. Data from studies that evaluated epidemiology of CC in
the Brazilian population were preferably used to calibrate the
model, particularly when addressing the Brazilian Amazon
population. The supplementary data illustrate the values of
the base case, variations of the sensitivity analysis, and the
data source used in the model. The base case values represent
the best estimate for each variable.
Where necessary, the model was calibrated by adjusting
the incidence of precursor lesions of CC to adequately simu-
late the results of cancer incidence as recorded in the Brazilian
Amazon region.
Precursor  lesions
The likelihood of oncogenic HPV-induced precursor lesions
was deﬁned in accordance with a Brazilian study that assessed
the incidence of squamous intraepithelial lesion in adoles-
cents who were followed up annually.13
For simpliﬁcation, LSIL was deﬁned as grade I lesions,
and HSIL was deﬁned as grade II and III lesions and in situ
carcinoma. The age of sexual initiation was assumed to be
13 years according to a local epidemiological study,4 and the
incidence of LSIL peaked one year after the initiation of sexual
intercourse.
Due to the paucity of epidemiological studies evaluat-
ing progression probabilities and the regression of precursor
lesions, this model used transition probabilities reported in
classic international studies adjusted for one year (one cycle),
assuming that the mechanism of evolution of the disease is
universal.14,15 The probability of precursor lesion regression
to normality was greater in younger women (< 30 years) com-
pared to those who were older than 30 years, reﬂecting more
persistent infections in older women.16
Cytological  screening  tests
The probability of detecting an asymptomatic cervical lesion
is a function of the percentage of women who undergo Pap
smear screening and the sensitivity and speciﬁcity of the test.
Incremental evaluations of vaccinations of the population
were performed for a non-screening scenario and for scenar-
ios in which individuals were screened three and ten times
throughout their lifetimes.
In the scenario of three screening exams throughout an
individual’s lifetime, the individuals from the model were sub-
jected to the Pap test randomly within the second, fourth, and
sixth decades of life. In the scenario of ten lifetime exams,
individuals were subjected to testing every ﬁve years from the
ages of 25 to 40, and then every three years until the age of
55, with a ﬁnal exam at 65 years of age, in accordance with
a Brazilian study that demonstrated that the frequency of
preventive examinations tends to be higher between 40 and
16The sensitivity of the Pap test was estimated at 70% for
LSIL and 80% for HSIL. The speciﬁcity ranged from 80% to 90%,
according to Brazilian studies.17–20
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The fundamental structure of the model is based on clini-
al practice consistent with the clinical program procedures
dvocated by VIVA MULHER, a program from the Brazilian
inistry of Health.21 Abnormal screening examinations were
orwarded to colposcopy, and tissues were evaluated by biopsy.
f HSIL was histologically conﬁrmed, then the patient would
e subjected to cryotherapy treatment or surgery. LSIL cases
nderwent new screening tests after six months.
The costs related to each procedure were derived from the
unds allocation table of the Brazilian Ministry of Health.21,22
nvasive  cervical  cancer
iven the progression to cervical invasive cancer, the proba-
ilities of its detection in the asymptomatic, early, regional, or
etastatic stages were derived from a local epidemiological
tudy, as were the costs allocated to the initial treatment of
ancer.4 The tumor stages were simpliﬁed as localized can-
er (FIGO stage I and IIA), regional cancer (FIGO IIB to IVA), or
etastatic cancer (FIGO IVB). The standardized treatment was
urgery for localized cancer, chemotherapy combined with
adiotherapy for regional cancer, and palliative chemotherapy
or metastatic cancer.4
The probabilities of death by cancer at each stage were
xtracted from the global survival curves of longitudinal
tudies.23 The ﬁve-year survival rate ranged from 92.0% for
ocalized cancer to 55.7% for regional cancer and 16.5%
or metastatic cancer. The annual incremental costs were esti-
ated at 10% of the initial value of the cancer treatment
nd refer to screening examinations, control of sequelae, and
reatment-related toxicities or costs related to tumor recur-
ence. Only direct costs that were assigned to cancer were
omputed, and were expressed in American dollars (US$).
uality  of  life
tility is a measure of the quality of life; it varies on a scale
rom 0 to 1, where 0 represents death and 1 represents ideal
ealth. The model multiplies the years of life by the utility
mplicated in the health status to adjust survival by quality of
ife; the ﬁnal outcome of effectiveness is quality-adjusted life
ears (QALYs). The supplementary data illustrate these values.
The completion of the Pap test implied a slight decrease
n the quality of life during the year of examination (0.99),
s did colposcopy examinations and conization (0.95). Can-
er precursor lesions of the uterine cervix were considered
symptomatic and caused no reduction in quality of life.
he quality of life (utility) related to each tumor stage was
ased on an international study that speciﬁcally addressed
his topic using a validated analog scale, and ranged from 0.48
metastatic cancer) to 0.76 (localized cancer).24 The use of util-
ty parameters from international studies as a reference in the
resent model can be explained by the absence of Brazilian
tudies addressing this issue, but may be supported by the
oncept of universality of human suffering.24accination  characteristics
he goal of this model is to evaluate the impact of the vaccine
n the incidence of CC exclusively. It was not developed to1 3;5  9(5):442–451 445
distinguish the effect of the bivalent from the quadrivalent
vaccine. The reduction in the incidence of CC-inducing lesions
as a result of vaccination was based on studies that originally
reported the effectiveness of the vaccine.6–8
The vaccination coverage was assumed at 90% of the target
population, based on the results of a recently conducted vacci-
nation campaigns against rubella in Brazil (in 2008 and 2011).25
In this nationwide vaccination strategy held in a similar pop-
ulation, the a 95% coverage was achieved among females aged
between 12 and 19 years. Whereas HPV vaccine requires three
applications (unlike rubella vaccine, which requires only one
dose), the assumed coverage for this model was slightly lower
(90%).
In the base case of this model, it was determined that the
vaccine provided immunity throughout life after three doses.
However, there are major concerns regarding the duration of
immunity, with signiﬁcant impact on the economic outcomes
of vaccination. Simulations on the need for booster doses to
maintain immunity (one to four doses throughout life) were
also performed. Booster vaccination required only one dose;
therefore, its cost was estimated at a third of the initial vacci-
nation.
There are no references for the price of the vaccine in Brazil
for the large-scale public sector, since the vaccine has not yet
been incorporated into public health protocols. A study con-
duct by the Brazilian Ministry of Health estimated the price
of vaccination at approximately US$ 180 (US$ 57 for each
dose + US$ 9 as cost of the applications).26 The Rotative Fund
(Pan-American Health Organization) for vaccine purchases
has been a technical cooperation mechanism for the expan-
sion of vaccination coverage.27 According to the Rotative Fund,
the cost of the vaccine dose to Brazil would be approximately
US$ 60 (US$ 17 for each dose + US$ 9 as cost of the appli-
cations). In the present model, the cost of initial vaccination
(three doses + implementation costs) for the base case was
estimated at US$150.
However, it was reported that the average price of vaccina-
tion (three doses) in the American market is US$ 360.28 For the
public sector, the value negotiated by the Centers for Disease
Control and Prevention in the United States was US$ 290.29
Measurement  of  outcomes
The results of the effectiveness were shown as the num-
ber of cancer cases prevented and deaths avoided, and the
utility outcomes were shown as QALYs. The incremental cost-
effectiveness ratio (ICER) was calculated by the ratio of the
difference in the cumulative total costs divided by the total
QALYs obtained per woman that are attributed to the addition
of vaccination to the existing screening program. As a thresh-
old for judgment, the international convention that a strategy
can be considered cost beneﬁcial if the ICER is less than the
value of GDP per capita (i.e., if the additional cost of a strategy
is less than the value of GDP per capita to save a QALY) was
followed.30,31Sensitivity  analysis
All economic assessments show a certain degree of
uncertainty, inaccuracy, or methodological controversy.12,31
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Table 1 – Health and economic outcomes for the addition of vaccination to the screening strategy (Pap test).
Preventive strategies Cost per individual
(US$)
Quality-adjusted life
years (QALYs)
Incremental
cost (US$)
QALYs saved
per individual
ICER (US$/QALY)
Non-screening scenario
Vaccination 270 24.8 -25 0.2 Dominant
No vaccination (natural course) 295 24.6
Scenario of three screenings throughout the lifetime (base case)
Vaccination + screening 320 29.6 165 0.2 825
Only screening 155 29.4
Scenario of ten screenings throughout the lifetime
immunization). For vaccination costs above US$ 500, the vac-
cination strategy requires approximately US$ 2,200 to save one
QALY. A vaccination effectiveness (reduction in the incidence
Vacc. coverage 50%
Vacc. coverage 70%
Vacc. coverage 100%
Pap smear 3x in life
Pap smear 10x in life
R
ed
uc
tio
n 
in
 C
C 
in
cid
en
ce
 (%
) 
Vacc. + Screening 10xVacc. + Screening 3xVaccination onlyScreening only
80
70
60
50
40
30
20
10
0Vaccination + screening 448 34.5 
Only screening 193 34.3
Therefore, sensitivity analyses (one-way) were performed for
variables with uncertainty over the base case values to assess
the robustness of the present study ﬁndings. These analy-
ses recalculate the ICER considering the variations in a given
parameter.
The evaluated variables were cost of vaccination, effec-
tiveness of vaccination, scenario of the pre-existing screening
program, vaccination coverage, time of immunity, annual dis-
count rate, and characteristics of the Pap test (sensitivity).
For such analyses, the variation values represent the authors’
judgment regarding the uncertainty of the study parameter or
the variations in the results that have been published in the
medical literature.
Results
Model  calibration
The primary outcome for the calibration of the model was the
incidence of invasive cancer. In the scenario of the natural
course of HPV infection, without screening exams, the model
simulated a 4.2% lifetime risk of cancer, which equates to 34.1
invasive CC cases per 100,000 women, considering the demo-
graphic structure of the region studied.11 In the scenario with
screening three times throughout an individual’s lifetime, the
risk of cancer was estimated at 3.4% (equivalent to 27.5 cases
per 100,000 women).
The model was well-calibrated to reported data of inci-
dence of CC in the Brazilian Amazon. The prediction in the
three-screenings scenario corresponded satisfactorily to
the gross incidence rate of invasive CC as recorded in the
Brazilian Amazon region in 2010 (28.2 cases per 100,000
women), and was considered as the baseline strategy to be
compared with the addition of vaccination.4
Base  case  analysis
With a vaccination coverage rate of 90%, the vaccination strat-
egy for preteen girls of the Brazilian Amazon region would
reduce the lifelong incidence of CC by 42% in this population,
and would reduce the mortality due to CC by approximately
43.4%. The addition of the vaccine would generate an incre-
mental cost of approximately US$ 165 per woman to the
current strategy. The incremental cost-effectiveness ratio was
US$ 825/QALY saved, given the base case parameters.255 0.2 1,275
This assessment can be compared to the addition of the
vaccine in other hypothetical scenarios of baseline cytological
screening in Table 1.
Fig. 2 compares the reduction in the incidence of CC for
the various strategies (combination of cytological screening
and vaccination), given the different vaccine coverage levels
simulated by this model. It is noteworthy that the goal of a
50% reduction in CC incidence could be achieved by combin-
ing high vaccination coverage (> 70%) with existing screening
procedures (> 3 Pap tests during lifetime).
Simulation  of  uncertainties
The sensitivity analyses reveal that vaccination tends to
provide a favorable proﬁle regarding cost-effectiveness,
despite changes in the base case parameters proposed by the
sensitivity analysis (Fig. 3).
The population vaccination coverage implies wide varia-
tions in ICER, surpassing US$ 2,000/QALY for vaccine coverage
levels of less than 50%. In a vaccination coverage of 100%, the
ICER would be approximately US$ 500/QALY. The vaccination
strategy tends to dominate the cytological screening (3x) in
isolation, i.e., it is less costly and more  effective (ICER ≤ 0)
for vaccination costs lower than US$ 40 (all doses for primaryFig. 2 – Effectiveness of strategies in the prevention of
cervical cancer. Additional effect of vaccination in different
vaccine coverage levels and preventive strategies.
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Fig. 3 – Sensitivity analysis. (A) Variation in vaccination coverage (30% to 100%); (B) variation in vaccination cost (US$ 15
to US$ 500); (C) annual discount rate variation (0% to 10%); (D) variation in vaccine effectiveness in reducing the incidence
o mbe
i
o
U
t
I
b
t
d
U
c
e
e
t
t
3
h
t
I
d
w
U
hf pre-malignant lesions (25% to 70%); (E) variation in the nu
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f precursor lesions) of above 40% maintains the ICER below
S$1,000/QALY compared to the basal strategy. Increases in
he sensitivity of the Pap test tend to modestly increase the
CER of added vaccination by improving the efﬁciency of the
aseline strategy, leading to a relative reduction in the addi-
ional beneﬁt of the vaccine.
If revaccination is needed (at least one lifetime booster
ose) for the maintenance of immunity, the ICER would be
S$ 1,650/QALY for the vaccination strategy, considering the
ost of the vaccine booster at US$ 50 per dose. The need of
xtra doses substantially raises the costs of vaccine strat-
gy without improving clinical effects, negatively altering
he cost-effectiveness proﬁle of vaccination. In the case of
he need for three booster doses, the ICER would reach US$
,200/QALY. The ICER would surpass US$ 4,000/QALY for the
ypothesis of a booster dose every 10 years (four booster doses
hroughout life).
The parameter variation with the greatest impact in the
CER was the annual discount rate. In an analysis without a
iscount rate, the ICER would be approximately US$ 30/QALY,
hich is substantially less than a discount rate of 10% (ICER =
S$ 4,500/QALY). These results are consistent with a lifetime
orizon cohort, as proposed in the present study.r of lifetime booster shots (1-4 booster shots); (F) variation
Discussion
Due to increasing healthcare costs worldwide and the growing
constraints arising from the scarcity of resources, healthcare
demands have increasingly sought to justify the incorpora-
tion of a new technique based on its cost-effectiveness or
cost-utility. To address this growing demand over the past
few decades, methodological tools that promote rationality
in decision-making in healthcare were proposed, aiming to
achieve efﬁcient use of available resources.
The present study revealed that the addition of HPV vacci-
nation to the existing preventive strategy exhibits a favorable
cost-effectiveness and cost-utility proﬁle in the Brazilian Ama-
zon region. Even when simulating a pessimistic vaccination
coverage rate (approximately 30%), the ICER of the addition of
vaccination does not exceed the conventional limit of the GDP
value per capita (about US$ 12,000 for Brazil in 2012) for any
other uncertainty simulation. The ICER values resulting from
the sensitivity analysis conﬁrms the favorable proﬁle of vacci-
nation even if the limit value used were the GDP per capita in
the Amazon region (US$ 6,350 per capita). If the cost of vacci-
nation is reduced to US$ 40 or less, with a vaccination coverage
 a s . 2448  r e v a s s o c m e d b r
rate of 90%, then adding vaccination tends to dominate the
cytological screening strategy used alone.
Some authors have proposed a different limit parameter
for developing countries, suggesting that an expense of one to
three times the value of GDP per capita for each QALY saved
would represent a good use of resources in these countries.30
Although there is no consensus in Brazil regarding the limit for
a strategy to be considered cost-effective, the present study
conﬁrms the favorable proﬁle of the addition of HPV vacci-
nation in Brazilian regions with poor prevention programs
and a high incidence of CC according to the proposed crite-
ria.
To better understand the implications of the HPV vac-
cine, cost-effectiveness analyses published in countries facing
opposing economic situations can be enlightening. Goldie
et al. studied the cost-effectiveness of the HPV vaccine in
72 low-income countries, mostly countries in Africa, which
are characterized by high CC incidence rates.32 The analysis
showed that the ICER of adding vaccinations in these countries
did not surpass US$ 200/QALY in 59 of the 72 countries, but had
a major impact on the reductions in mortality and incidence
rates of CC after the vaccination of preteens. The analysis
also showed the favorable cost-effectiveness proﬁle of the vac-
cine in regions where CC was not controlled by conventional
screening programs.
Conversely, in developed countries that succeeded in
controlling CC incidence and CC-related mortality with
solid gynecological screening programs, the HPV vaccine is
not as favorable from a cost-effectiveness standpoint Ire-
land, the United Kingdom, Switzerland, and Finland have
gross incidence rates under 10 cervical cancer cases per
100,000 women. In these countries, cost-effectiveness stud-
ies showed an additional cost of over US$ 20,000/QALY.33–36
In the United States, the ICER of adding vaccination exceeded
US$ 43,000/QALY37. In the Netherlands, the CC incidence rate
is less than six cases per 100,000 women; however, the ICER
of adding the HPV vaccine to the existing Dutch preventive
program was greater than US$ 70,000/QALY, classifying the
vaccination strategy, according to the authors, as non-cost-
effective.38
These evidences suggest that the greatest beneﬁt of the
vaccine does not lie in its synergy with the basal population
screening programs, rather in their replacement in countries
or regions whose programs are insufﬁcient and poorly struc-
tured, and have a high prevalence of oncogenic HPV infection.
Despite the favorable economic proﬁle, the costs involved
in the vaccination of preteen girls have caused widespread
concern, especially in developing countries. The HPV vaccine
(16 and 18) is one of the most expensive vaccines on the
market, hindering its incorporation in the healthcare systems
of countries that would most beneﬁt from this technology.
According to the lesson learned from the vaccine against hep-
atitis B, which is now available for children in 89% of the
world’s countries, including the poorest countries, only after
a drastic reduction in its price was vaccination in global pro-
portions possible.39Although the cost of the vaccine is the main barrier
to its introduction in Latin America, other factors are also
important, such as the feasibility of vaccinating the tar-
get population, the competition with other vaccines, and its 0 1 3;5  9(5):442–451
acceptance. The cultural acceptance of the vaccine has not
been evaluated in Brazil. It is worth noting that the general
public and health managers’ knowledge of HPV and its impli-
cations are factors that strongly inﬂuence the acceptance of
the vaccine by a population. Accordingly, strategies of commu-
nication and education regarding the subject would be crucial
to the success and effectiveness of any public health policy
for the introduction of the HPV vaccine in Brazil, particularly
in the Amazon region.
There are limitations to the present study. First, due to lack
of national data, some parameters have been calibrated based
on international data. Second, the Markov assumption itself
establishes that transition probabilities depend exclusively on
the current health state, not on a sequence of past health
states. Indeed, dynamic transmission models represent an
economic evaluation methodology that uses probabilistic vari-
ations to more  reliably simulate the natural course of diseases
such as CC, but requires large and robust epidemiological
data for its preparation (not commonly available). Finally, the
present study considered only the effects of the vaccine on
the magnitude of CC, without considering the effects of the
vaccine in reducing other types of cancer, such as those of the
vulva, vagina, anus, or head and neck, nor the beneﬁts of the
quadrivalent vaccine on genital warts.
A recent study evaluated the cost-effectiveness of the
quadrivalent HPV vaccine in Brazil, using a dynamic transmis-
sion model to assess the effects on CC and genital warts.40
Kawai et al. estimated that the ICER of vaccination strat-
egy varied from US$ 448 to US$ 698/QALY when considering
only the bivalent vaccine (16 and 18) for control of the CC.
The study also reported an even better outcome when con-
sidering the effect of the quadrivalent vaccine to control
CC and genital warts (US$ 219 to US$ 450/QALY). This data
suggest that, if the additional beneﬁt of vaccine is con-
sidered, a more  favorable cost-effectiveness proﬁle may be
achieved.
The HPV vaccine may also be effective in preventing
male cancers (such as those of the penis and anus). Addi-
tionally, male vaccination may improve the protection of
women by reducing viral transmission. The cost-effectiveness
of including Brazilian boys in HPV vaccination was studied
by Kim et al.41 This strategy rendered a small additional
gain in clinical beneﬁt (around 4% reduction in risk of HPV-
related cancer), but a high additional cost. The authors judged
vaccinating boys as non-cost-effective and recommended that
efforts should be focused on expanding the coverage of girls
only.
The high risk of invasive CC in the Brazilian Amazon region
implies an urgent need to rethink the current preventive pol-
icy, especially for underprivileged regions of the country. The
present study was the ﬁrst cost-effectiveness analysis of a
CC preventive strategy directed toward a speciﬁc region of
the country. The cost-effectiveness analysis of HPV vaccine
for the Amazon region showed a better proﬁle when com-
pared to studies addressing this topic to Brazil as a whole,
as in the analysis published by Colantônio et al. (ICER = US$
42 4310,181/QALY) and by Goldie et al. (ICER = US$ 9,600/QALY).
Regarding public health, these results lead to the conclusion
that public policies on women’s health, particularly on CC
prevention programs, should be decentralized (adjusted to
s . 2 0 
r
i
B
r
p
h
p
V
P
P
T
D
I
Pr e v a s s o c m e d b r a 
egional reality) rather than uniform, given the heterogene-
ty inherent in a country of continental proportions, such as
razil.
Large-scale preteen vaccination in the Brazilian Amazon
egion can be considered an investment in the future to
revent, in the coming decades, the premature deaths of
undreds of women who have historically been neglected in
reventive government programs.
ariables B
roperties of vaccination
Vaccination coverage – three doses (%) 9
Vaccination age (years) 1
Duration of immunity (years) l
Adherence to booster vaccination (%) 9
reventive screening properties
Number of tests during the lifetime (n) 3
Age screening started (years) 1
Sensitivity of Pap test (in LSIL scenario) (%) 7
Sensitivity of Pap test (in HSIL scenario) (%) 8
Speciﬁcity of Pap test (%) 9
ransition probabilities
Develop LSIL after ﬁrst sexual intercourse
1st year 0
2nd year 0
3rd year 0
4th year 0
5th to 25th year (mean) 0
26th to 50th year (mean) 0
After 51st year (mean) 0
Reduction in the probabilities of developing LSIL
attributed to vaccination (%)
5
LSIL regression (< 30 years old) 0
LSIL regression (> 30 years old) 0
evelop HSIL from LSIL 0
Develop invasive cancer from LSIL 0
Regression of HSIL 0
Develop invasive cancer from HSIL 0
nvasive cervical cancer properties
Probability of localized cancer at diagnosis 0
Probability of regional cancer at diagnosis 0
Probability of metastatic cancer at diagnosis 0
Probability of death – localized 0
Probability of death – regional 0
Probability of death – metastatic 0
recursor lesions treatment properties
Effectiveness of cryosurgery for LSIL (%) 8
Effectiveness of cryosurgery for HSIL (%) 7
Eligibility for cryosurgery (%) 81 3;5  9(5):442–451 449
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Appendix  A.
Model parameters, costs, utilities, variation for the sensitivity
analysis, and respective sources
ase case Variation§ Data source
(reference)
0 30-100 25
2 4,13
ifetime 10-lifetime 9
0 25
 0-10 4
8 estimated
0 50-90 17,18
0 60-90 19,20
0 17,18
13
.285 4,13
.117 4,13
.114 4,13
.075 4,13
.070 (± 0.022) 4,13
.053 (± 0.012) 4,13
.010 (± 0.008) 4,13
0 40-70 6,7,8
.193 14, 15, 16
.113 14, 15, 16
.110 14, 15
.00075 14, 15
.175 14, 15
.0078 14, 15
.315 4
.488 4
.197 4
.0165 23
.1101 23
.305 235
5
5 estimated
r450  r e v a s s o c m e d b r a s . 2 0 1 3;5  9(5):442–451
Appendix A (Continued )
Variables Base case Variation§ Data source
(reference)
Others
Duration of cycle (years) 1 estimated
Age of sexual initiation (years) 13 4
Discount rate (%) 5 0-10 12, 31
Costs (US$)
Vaccination – three doses 150 15 - 500 26, 27, 28, 29
Booster shot 50 26, 27
Pap test 8 22
Medical appointment 5.5 22
Colposcopy 26.8 22
Cryosurgery 26.8 22
Conization 498 22
Hysterectomy type 1 1,236 22
Localized invasive cancer treatment 3,702 4
Regional invasive cancer treatment 8,420 4
Metastatic cancer treatment 2,625 4
Utilities
Normal population 1 estimated
Completion of Pap test (for 1 year) 0.99 estimated
Colposcopy and conization (for 1 year) 0.95 estimated
Localized invasive cancer 0.76 24
Regional invasive cancer 0.67 24
Invasive metastatic cancer 0.48 24
§  Range of variation addressed in sensitivity analysis of variables where lies any uncertainty. Costs expressed in American dollars (US$).
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